Gaston Stanislas Marcella Diels

This inventor holds 20 USPTO granted patents and 6 published patent applications, plus 7 CIPO patents and 10 EPO patents, primarily in Nucleoside Analogues. Top assignees: Janssen Pharmaceutica Nv, Other. Active years: 2002-2024.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Gaston Stanislas Marcella Diels. Retrieved from https://idiyas.com/inventor/gaston-stanislas-marcella-diels

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 20 (Patent Applications = 6)

% Patents Active = 80.0

CIPO Patents = 7 (Patent Applications = 6)

EPO Patents = 10 (Patent Applications = 13)

Average Co-Inventor Count = 7.6

ph-index = 5

Forward Citations = 153(Granted Patents)

Location History:

Ravels, BE (2002 - 2016)
Beerse, BE (2005 - 2018)
Turnhout, BE (2020 - 2024)

Company Filing History:

19 out of 2,101

Janssen Pharmaceutica Nv

patents

1 out of 834,570

Other

patents

Years Active: 2002-2024

Loading Chart...

Areas of Expertise:

PRMT5 Inhibitors

Nucleoside Analogues

MALT1 Inhibitors

Pyrazole Derivatives

Quinazoline Derivatives

Heteroaryl Amines

Neurokinin Antagonists

Thiazolyl Derivatives

Antiproliferative Agents

GSK3 Inhibitors

Macrocyclic Compounds

Azauracil Derivatives

20 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 11993614 - Monocyclic and bicyclic ring system substituted carbanucleoside analogues for use as PRMT5 inhibitors (2024-05-28),

2. 11883367 - 6-6 bicyclic aromatic ring substituted nucleoside analogues for use as PRMT5 inhibitors (2024-01-30),

3. 11318157 - 6-6 bicyclic aromatic ring substituted nucleoside analogues for use as PRMT5 inhibitors (2022-05-03),

4. 11098062 - Monocyclic and bicyclic ring system substituted carbanucleoside analogues for use as PRMT5 inhibitors (2021-08-24),

5. 11040031 - Pyrazole derivatives as MALT1 inhibitors (2021-06-22),

6. 10898504 - Substituted nucleoside analogues for use as PRMT5 inhibitors (2021-01-26),

7. 10888550 - Pyrazole derivatives as MALT1 inhibitors (2021-01-12),

8. 10653711 - 6-6 bicyclic aromatic ring substituted nucleoside analogues for use as PRMT5 inhibitors (2020-05-19),

9. 10017509 - Macrocylic pyrimidine derivatives (2018-07-10),

10. 9273013 - Quinazoline derivatives (2016-03-01),

11. 8394786 - Quinazoline derivatives (2013-03-12),

12. 8338422 - Indolin-2-ones and aza-indolin-2-ones (2012-12-25),

13. 8318731 - Pyrrolopyrimidines (2012-11-27),

14. 7648975 - Macrocyclic quinazoline derivatives as antiproliferative agents (2010-01-19),

15. 7514445 - Heteroaryl amines as glycogen synthase kinase 3β inhibitors (GSK3 inhibitors) (2009-04-07),

Title: Innovations by Gaston Stanislas Marcella Diels

Introduction

Gaston Stanislas Marcella Diels is a prominent innovator based in Ravels, Belgium. With a substantial portfolio of 20 patents to his name, Diels has made significant contributions to the field of medicinal chemistry. His innovative work primarily focuses on developing compounds that inhibit PRMT5, a vital protein in various biological processes.

Latest Patents

Among his latest innovations are two notable patents. The first patent concerns "Monocyclic and bicyclic ring system substituted carbanucleoside analogues for use as PRMT5 inhibitors." This invention includes novel compounds of Formula (I), designed to function as effective inhibitors of PRMT5, along with pharmaceutical compositions for their use as medicaments.

The second patent features “6-6 bicyclic aromatic ring substituted nucleoside analogues for use as PRMT5 inhibitors.” This invention also highlights compounds of Formula (I) that play a crucial role in inhibiting PRMT5 and outlines their potential as active ingredients in pharmaceutical formulations.

Career Highlights

Throughout his career, Gaston Diels has collaborated with industry leaders, including Janssen Pharmaceutica NV, where he has honed his expertise in drug development. His work has made significant strides in therapeutic applications, showcasing his dedication to advancement in medicinal research.

Collaborations

Diels has worked alongside notable colleagues, including Eddy Jean Edgard Freyne and Tongfei Wu. Their combined efforts contribute to the impactful research emerging from their collaborations, further supporting advancements in the pharmaceutical industry.

Conclusion

Gaston Stanislas Marcella Diels stands as a distinguished figure in the realm of pharmaceutical innovations. His 20 patents, focusing on PRMT5 inhibitors, underline the importance of his work in addressing critical health challenges. Through collaborative efforts and a commitment to pioneering research, Diels continues to push the boundaries of medicinal chemistry, offering hope for future medical therapies.

Profile summary based on public USPTO records.